Eli Lilly, an American pharmaceutical company recorded quarterly revenue of $6,488 million in Q2 2022 and reported a 16.9% decline in quarterly revenue compared to $7,810 million in Q1 2022.
Eli Lilly operates as a single operational segment dedicated to the worldwide development, production, marketing, and distribution of pharmaceutical goods, and generated the majority of its earnings from goods made in its facilities. It segregated its revenue in different geographic areas namely the US ($3,934.8 million), Europe ($1,101.1 million), Japan ($454.4 million), China ($352.1 million), and the Rest of the World ($645.7 million). The company's primary manufacturing facilities are located in the United States, alongside manufacturing facilities in Puerto Rico, and Ireland. In Q4 2021, revenue rose because of increased sales volume Operating expenses grew in 2021 owing to increasing development costs for pharmaceutical products.
After the first quarter of 2022, the company anticipates that the sales of bamlanivimab and etesevimab will only provide a little amount of additional revenue.
Bamlanivimab and Etesevimab:
To treat covid-19, the drug bamlanivimab/etesevimab combines two monoclonal antibodies, bamlanivimab and etesevimab, which are both directed at the spike protein of SARS-CoV-2. It is given together via intravenous infusion and to neutralize the virus, it was created to prevent viral attachment and entry into human cells.
United States of America
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer